Abstract
To compare 123I-metaiodobenzylguanidine (MIBG) and [Fluorine-18]-2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in 22 patients with phaeochromocytomas
and paragangliomas (PGL) retrospectively and to evaluate the correlation between FDG
uptake and Ki-67 proliferative index. Fourteen of 17 (82%) patients at initial diagnosis
had positive FDG uptake, more intensely in PGL. Eleven of 12 (92%) patients had positive
MIBG uptake. PET and MIBG scintigraphy were concordant in 10 patients, discordant
in 6. Combined results yielded no false negative findings and are complementary. Neither
maximum standardised uptake value nor visual scores on MIBG correlated with Ki-67.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pheochromocytoma: presentation, diagnosis and treatment.J Hypertens. 2006; 24: 2331-2339
- Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma.Semin Oncol. 2013; 40: 120-133
- Contemporary adrenal scintigraphy.Eur J Nucl Med Mol Imaging. 2007; 34: 547-557
- Positron emission tomography: current status and future challenges.Intern Med J. 2010; 40: 19-29
- Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET.Radiology. 1999; 212: 35-41
- MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy.Clin Nucl Med. 2005; 30: 579-581
- Discordant localization of 2-[18F]-fluoro-2-deoxy-d-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites.Nucl Med Commun. 2006; 27: 31-36
- Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomas.Histopathology. 2003; 43: 62-71
- Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.J Clin Endocrinol Metab. 2011; 96: 717-725
- Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.J Clin Oncol. 2007; 25: 2262-2269
- Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.Eur J Nucl Med Mol Imaging. 2010; 37: 484-493
- The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel–Lindau syndrome.Eur J Endocrinol. 2007; 156: 483-487
- [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.Ann Surg Oncol. 2006; 13: 187-197
- The efficacy of Iodine-123-MIBG as a screening test for pheochromocytoma.J Nucl Med. 1994; 35: 1138-1144
- 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.Eur J Nucl Med Mol Imaging. 2012; 39: 1977-1995
- Modern nuclear imaging for paragangliomas: beyond SPECT.J Nucl Med. 2012; 53: 264-274
- Comparison of 18F-Fluoro-l-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.J Clin Endocrinol Metab. 2009; 94: 4757-4767
Article info
Publication history
Published online: September 16, 2013
Accepted:
July 24,
2013
Received:
May 17,
2013
Footnotes
☆Conflict of interest: None.
☆☆Funding source: None.
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
